Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2019 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

PHOENIX, Jan. 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
December 18, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone

PHOENIX, Dec. 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
December 17, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology

PHOENIX, Dec. 17, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
December 04, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy

PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and...
November 20, 2018 07:00 ET | Source: INSYS Therapeutics, Inc.

Clinical Data from Long-Term Safety-Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting

PHOENIX, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Clinical data from a long-term safety study of pharmaceutical-grade cannabidiol (CBD) oral solution as an investigational treatment for refractory...
November 05, 2018 16:16 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Reports Third Quarter 2018 Results

Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS...
November 05, 2018 16:15 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets

Company Reiterates Focus on Pharmaceutical Cannabinoids and Spray Technology PHOENIX, Nov. 05, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development,...
November 01, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus Intramuscular and Intravenous Naloxone for Opioid Overdose

PHOENIX, Nov. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), today announced that a pharmacokinetic (PK) study (INS012-18-119) of its proprietary intranasal naloxone spray...
October 22, 2018 17:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5

PHOENIX, Oct. 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
October 12, 2018 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies

PHOENIX, Oct. 12, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...